EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Alk-rearranged lung adenocarcinoma: From molecular genetics to therapeutic targeting

Ugo Testa iD, Germana Castelli, Elvira Pelosi

Tumori Journal · 2024

DOI: 10.1177/03008916231202149 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Tumori Journal, 2024. Verfasst von Ugo Testa und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Istituto Superiore di Sanità, Italy. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Lung Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anaplastic Lymphoma Kinase (ALK) is a potent oncogenic driver of lung adenocarcinoma (LUAD). ALK is constitutively activated by gene fusion events between the ALK and other gene fusion partners in about 2-3% of LUADs, characterized by few other gene alterations. ALK-fusions are a druggable target through potent pharmacological inhibitors of tyrosine kinase activity. Thus, several ALK-TKIs (Tyrosine Kinase Inhibitors) of first-, second- and third-generation have been developed that improved the outcomes of ALK-rearranged LUADs when used as first- or second-line agents. However, resistance mechanisms greatly limit the durability of the therapeutic effects elicited by these TKIs. The molecular mechanisms responsible for these resistance mechanisms have been in part elucidated, but overcoming acquired resistance to ALK-derived therapy remains a great challenge. Some new therapeutic strategies under investigation aim to induce long-term remission in ALK-fusion positive LUADs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenocarcinoma of LungLung NeoplasmsHumansAnaplastic Lymphoma KinaseCarcinoma, Non-Small-Cell LungDrug Resistance, NeoplasmProtein Kinase InhibitorsReceptor Protein-Tyrosine Kinases

Stichwörter der Autor:innen

ALK inhibitorsMolecular oncologymolecular resistancetarget therapythoracic oncology

Substanzen

Anaplastic Lymphoma KinaseProtein Kinase InhibitorsReceptor Protein-Tyrosine Kinases

Autor:innen und Institutionen

  • Department of Oncology, Istituto Superiore di Sanità, Italy.

ORCID-Profile: Ugo Testa

Zitieren

APA

Testa, U., Castelli, G., & Pelosi, E. (2024). Alk-rearranged lung adenocarcinoma: From molecular genetics to therapeutic targeting. Tumori Journal. https://doi.org/10.1177/03008916231202149

Vancouver

Testa U, Castelli G, Pelosi E. Alk-rearranged lung adenocarcinoma: From molecular genetics to therapeutic targeting. Tumori Journal. 2024. doi:10.1177/03008916231202149

BibTeX
@article{Testa2024,
  author = {Testa, Ugo and Castelli, Germana and Pelosi, Elvira},
  title = {Alk-rearranged lung adenocarcinoma: From molecular genetics to therapeutic targeting},
  journal = {Tumori Journal},
  year = {2024},
  doi = {10.1177/03008916231202149}
}
Kostenlos starten →